Key result
Triple therapy was prescribed to 94.2% of patients with an OAT indication post-PCI for the first 3 months, with DOACs frequently prescribed at inappropriately reduced doses.
Why the study?
Limited data exist on real-world prescribing for patients requiring oral anticoagulation who undergo PCI, and the clinical benefit of recommended triple therapy over dual therapy remains unclear.
What are the real-world prescribing strategies for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention?
Cohort (n=103)
Yes
What are the real-world prescribing strategies for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention?
Real-world data from Ireland shows widespread use of triple therapy post-PCI in patients with an OAT indication, frequently utilizing inappropriately reduced DOAC doses.
Answers are grounded in this paper and cite their sources.
Informs real-world OAT prescribing post-PCI; hypothesis-generating and should not yet change practice.
Background: Limited data are available regarding real-world prescribing in patients with an indication for oral anticoagulation (OAT) who undergo percutaneous coronary intervention (PCI). Most current guidelines recommend a period of triple therapy with OAT and dual antiplatelet (DAPT) agents over dual therapy with an OAT and DAPT but the clinical benefit is still unclear giving rise to limited evidence-based recommendations. Aim: To analyze the appropriateness of OAT and anti-platelet strategies post PCI in a real-world cohort of patients in 2 academic teaching hospitals. Methods and Results: In total, 103 patients were retrospectively analyzed. As the initial 3 month stragey, 97 patients (94.2%) received triple therapy, 4 received Dual Therapy (3.9%) and 2 received DAPT (1.9%). Patients with predominant bleeding risk were significantly less likely to receive triple therapy (75% vs. 95.7% vs. 95.8%, P < 0.05). Apixaban was the most common OAT (65.7%) which in most cases was prescribed at an inappropriately reduced dose of 2.5 mg BD (80.4%). The MACE, bleeding and all-cause mortality rates did not differ significantly between groups. Discussion: Our study demonstrates the widespread use of triple therapy for the first 3 months of treatment in 2 Irish academic hospitals. DOACs were prescribed in most cases at reduced doses not currently known to prevent stroke. This study highlights the need for more explicit management algorithms to improve evidence-based management in this area.
No takes yet. Share an insight, caveat, or question.
Kerley et al. (2020) conducted a cohort in Indication for oral anticoagulation undergoing percutaneous coronary intervention (n=103). Triple therapy (OAT and DAPT) vs. Dual therapy or DAPT was evaluated on Appropriateness of OAT and anti-platelet strategies post PCI. Triple therapy was prescribed to 94.2% of patients with an OAT indication post-PCI for the first 3 months, with DOACs frequently prescribed at inappropriately reduced doses.
Synapse has enriched 10 related papers. Consider them for comparative context: